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Introduction: The aim of this study was to identify anaplastic lym-
phoma kinase (ALK) rearrangements in lung cancer patient-derived 
xenograft (PDX) models and to explore their responses to crizotinib.
Methods: Screening of 99 lung cancer PDX models by the 
NanoString ALK fusion assay identified two ALK-rearranged non–
small-cell lung cancer (NSCLC) tumors, including one harboring a 
previously known echinoderm microtubule-associated protein-like 4 
(EML4)–ALK fusion and another containing an unknown ALK fusion 
variant. Expression array, RNA-Seq, reverse transcription poly-
merase chain reaction, and direct sequencing were then conducted to 
confirm the rearrangements and to identify the novel fusion partner 
in the xenograft and/or the primary patient tumor. Finally, pharma-
cological studies were performed in PDX models to evaluate their 
responses to ALK inhibitor crizotinib.
Results: Two ALK-rearranged NSCLC PDX models were identified: 
one carried a well-known EML4–ALK variant 3a/b and the other har-
bored a novel huntingtin interacting protein 1 (HIP1)–ALK fusion gene. 
Exon 28 of the HIP1 gene located on chromosome 7 was fused to exon 
20 of the ALK gene located on chromosome 2. Both cases were clinically 
diagnosed as squamous cell carcinoma. Compared with the other lung 
cancer PDX models, both ALK-rearranged models displayed elevated 
ALK mRNA expression. Furthermore, in vivo efficacy studies demon-
strated that, similar to the EML4–ALK-positive model, the HIP1–ALK-
containing PDX model was sensitive to treatment with crizotinib.
Conclusions: Discovery of HIP1 as a fusion partner of ALK in 
NSCLC is a novel finding. In addition, the HIP1–ALK-rearranged 
tumor is sensitive to treatment with crizotinib in vivo, implicat-
ing HIP1–ALK as an oncogenic driver of lung tumorigenesis. 
Collectively, our results indicate that HIP1–ALK-positive NSCLC 
may benefit from clinical applications of crizotinib.
Key Words: Huntingtin interacting protein 1, anaplastic lymphoma 
kinase, HIP1–ALK, Echinoderm microtubule-associated protein-
like 4, EML4–ALK, Non–small-cell lung cancer, Crizotinib (PF-
02341066), Patient-derived xenograft (PDX) tumor model.
(J Thorac Oncol. 2014;9: 285–294)
Tyrosine kinases have been widely recognized as attractive targets for molecularly targeted cancer therapy. Over the 
last decade a greater understanding of the molecular charac-
teristics of non–small-cell lung cancer (NSCLC) has led to the 
development of effective targeted therapies for personalized 
medicine in a subset of patients. Targeting activating epidermal 
growth factor receptor (EGFR) mutations was the first break-
through. Activation by mutation in EGFR in NSCLC correlated 
with clinical response to EGFR tyrosine kinase inhibitors.1,2 
Afterward, in 2007, echinoderm microtubule-associated pro-
tein-like 4 (EML4)–ALK fusion-type tyrosine kinase was iden-
tified as an oncoprotein in 4% to 5% of NSCLC cases.3 Clinical 
trials were soon initiated to investigate the role of crizotinib 
(PF-02341066), an oral selective inhibitor of ALK and hepato-
cyte growth factor receptor (c-MET) kinases,4 for the treatment 
of EML4–ALK-positive NSCLC.5 On the basis of response 
rates reported in phase 1 and 2 clinical trials, crizotinib received 
accelerated approval by U.S. Food and Drug Administration in 
August 2011 for the treatment of patients with locally advanced 
or metastatic NSCLC that is ALK-positive as detected by the 
ALK fluorescence in situ hybridization test.
EML4–ALK is generated as a result of a small inversion 
within the short arm of human chromosome 2.3,6,7 EML4–ALK 
undergoes constitutive dimerization through interaction between 
the coiled-coil domain within the EML4 region of each mono-
mer, thereby activating ALK and generating oncogenic activ-
ity. Besides EML4, other fusion partners of ALK have been 
reported in a variety of cancer types (primarily in hemato-
poietic malignancies), including nucleophosmin (NPM),8,9 
TRK-fused gene (TFG),10 clathrin heavy chain (Hc) (CLTC),11 
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5-aminoimidazole-4-carboxamide ribonucleotide formyltransfer-
ase/IMP cyclohydrolase (ATIC),12,13 cysteinyl-tRNA synthetase 
(CARS),14 moesin (MSN),15 tropomyosin 3 (TPM3),16,17 kinesin 
family member 5B (KIF5B),18 kinesin light chain 1 (KLC1),19 and 
tyrosine-protein phosphatase non-receptor type 3 (PTPN3).20 To 
date, only EML4–ALK, TFG–ALK, KIF5B–ALK, KLC1–ALK, 
and ALK–PTPN3 have been identified in lung cancer.21 Although 
the biological and clinical significance of these variants requires 
further investigation, it seems that not all of the above mentioned 
ALK rearrangements respond to crizotinib. For example, an ALK–
PTPN3 variant may not respond to crizotinib, as the ALK kinase 
domain is absent.21 In addition, other, not-yet-characterized 
fusions may also exist in solid tumors, including lung cancer.6
We report here a novel ALK fusion associated with 
NSCLC involving the HIP1 gene and demonstrate the sensi-
tivity of a HIP1–ALK-rearranged tumor to treatment with the 
ALK inhibitor crizotinib.
MATERIALS AND METHODS
Establishment of NSCLC PDX Models
In compliance with the protocol approved by the Institutional 
Review Board of Cancer Institute and Hospital of Chinese Academy 
of Medical Sciences and with the subject’s informed consent, pri-
mary tumor tissues were collected for PDX establishment. In brief, 
surgically resected primary tumor tissues from patients (designated 
as PA) were collected, trimmed, cut into 20- to 30-mm3 fragments 
and immediately implanted subcutaneously by using an 18-gauge 
trocar in the fore and/or hind bilateral flanks of 6- to 8-week-old 
female BALB/c nude mice (Shanghai SLAC Laboratory Animal 
Co., Ltd., Shanghai, China). Once the first generation of xenografts 
(designed as P0) was established and tumor sizes reached 500 
to 800 mm3, serial implantations in BALB/c nude mice were per-
formed to expand the xenograft tumors (i.e., P1, P2, P3, and beyond). 
Tumor size was measured periodically using a digital caliper (Cal 
Pro, Sylvac, Switzerland). Tumor volume was calculated as 0.5 × 
length × width.2 All procedures and protocols were approved by the 
Institutional Animal Care and Use Committee of WuXi AppTec.
Histology
Pieces of patient samples or PDX tissues at each pas-
sage were fixed in 10% buffered formalin for 24 to 48 hours 
and then paraffin-embedded. Five μm sections were cut and 
stained with hematoxylin and eosin. Histopathology was 
reviewed by a pathologist (WS).
Total RNA Isolation
Total RNA was isolated from the primary patient tumors and 
xenografts at P3 (LU-01-0015) or P2 (LU-01-0319) mouse models 
by using an RNeasy protect Mini Kit (Qiagen, Valencia, CA).
NanoString Assay for ALK Fusions
The method for the detection of ALK fusions and expres-
sions using NanoString’s nCounter technology (NanoString 
Technologies, Inc., Seattle, WA) has been described previously.22 
In brief, after incubation of total RNA with nCounter probe 
sets, the samples were transferred to the nCounter Prep Station 
(NanoString Technologies, Inc.), where excess probes were 
removed and probe/target complexes were aligned and immo-
bilized in the nCounter Cartridge (NanoString Technologies, 
Inc.). Cartridges containing immobilized and aligned reporter 
complex were subsequently imaged on an nCounter Digital 
Analyzer (NanoString Technologies, Inc.) set at 1155 fields 
of view. Reporter counts were collected using NanoString’s 
nSolver analysis software version 1. The raw data were normal-
ized and analyzed in two steps as previously described.22
A single-tube, multiplexed assay system was designed 
to simultaneously detect ALK fusion transcripts and mea-
sure the expression levels of several ALK exons flanking the 
fusion breakpoint. For fusion detection, ALK fusion part-
ner EML4-, KIF5B-, or TFG-specific 5′ capture probes and 
ALK-specific 3′ reporter probes were designed to hybridize 
to ALK fusion partner and ALK at the fusion junction, respec-
tively. The capture probes were able to detect all major variants 
of EML4-ALK fusions (variants 1, 2, 3a, 5, and “V5”21,23) and 
non–EML4–ALK fusions, including KIF5B–ALK and TFG–
ALK. For ALK gene expression, probe sets across the entire 
ALK transcript, including four probe sets designated as ALK 
5 ′-1 to 5 ′-4 located upstream of the intron 19 fusion break-
point and four probe sets ALK 3 ′-1 to 3 ′-4 located downstream 
of the fusion breakpoint, were designed to measure the expres-
sion levels of ALK exons flanking the fusion breakpoint. For 
fusion detection, a reporter count of 60 was designated as the 
background threshold level, and the fusion was called present 
if the normalized reporter count was higher than background 
threshold. For ALK gene expression, the ALK 3′ overexpression 
score (i.e., ALK3 ′/5′ ratio) was defined as follows: ALK3′/5′ = 
E
3
/max(A
5
, B), where E
3
 is the geometric mean of ALK 3′ probe 
expression, A
5
 is the average of the ALK 5′ probe expression, 
and B is the background threshold. The fusion was called pres-
ent if the ALK 3′ overexpression score was greater than two.
Microarray for ALK Expression
Total RNA was amplified and fragmented using a 
GeneChip 3′ IVT Expression Kit (Affymetrix, Santa Clara, CA). 
Then the samples were hybridized onto a GeneChip PrimeView 
Human Gene Expression Array or GeneChip Human Genome 
U133 Plus 2.0 Array (Affymetrix) and scanned on a Affymetrix 
GeneChip Scanner 3000 7G (Affymetrix). Data were subject to 
in-house bioinformatics analysis. In brief, the raw CEL data of 
the PrimeView and U133 Plus 2.0 Arrays were processed on an 
Expression Console (version 1.1, Affymetrix). Signal intensi-
ties of both arrays were normalized by the Robust Multiarray 
Average normalization approach.
Paired-End RNA-Seq Analysis
RNA-Seq library was generated using the Illumina 
TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, CA) 
and sequencing was performed on the Illumina HiSeq 2000 plat-
form (Illumina). Human sequence reads were isolated from the 
mixture of reads arising from the mouse host and reads arising 
from xenograft tumors by using a specific tool Xenome.24 The 
purified reads were then mapped to the Ensembl GRCh37.62 
B (hg19) reference genome using an RNA sequence aligner 
TopHat 2,25 which can align reads across splice junctions with 
or without relying on gene annotation. On the basis of the 
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aligned result, transcript assembly and abundance estimation 
were performed with the software Cufflinks, a well-established 
transcript assembler,26 and fusion transcripts were discovered 
with the enhanced TopHat-Fusion module.27
Reverse Transcription Polymerase Chain 
Reaction and Direct Sequencing
Total RNA (1 μg) was reversely transcribed into sin-
gle-stranded cDNAs using High Capacity cDNA Reverse 
Transcription Kits (Life Technologies, Carlsbad, CA) fol-
lowing the manufacturer’s instructions. One microliter of 
cDNA was used for a subsequent 25-μl polymerase chain 
reaction (PCR) amplification using a Premix PrimeSTAR HS 
PCR amplification kit (Takara Bio, Otsu, Shiga, Japan). To 
detect fusion transcript, we designed forward- and reverse-
primer combinations targeting the sequences flanking the 
breakpoint detected by RNA-Seq. For HIP1–ALK fusion, the 
forward primer (5′-CGGCCAGAATAGAGGGTACA-3′) 
tar geting the 5′ partner gene HIP1 and reverse primer (5′- 
CACCTGGCCTTCATACACCT-3′) targeting the 3′ partner ALK 
were used. For EML4–ALK fusion, the previously described for-
ward primer (5′-TACCAGTGCTGTCTCAATTGCAGG-3 ′) and 
reverse primer (5′-TCTTGCCAGCAAAGCAGTAGTTGG-3′) 
were used to detect EML4–ALK variant 3a/3b28. The PCR 
products were sequenced by conventional direct sequenc-
ing (BioSune Biotechnology (Shanghai) Co., Ltd., Shanghai, 
China) by using an ABI 3730 DNA Sequencer (Applied 
Biosystems, Foster City, CA). The results were compared with 
the reference sequence to validate the fusion transcripts.
In Vivo Efficacy Study
Crizotinib [(R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-
ethoxy]-5-(1-piperidin- 4-yl-1H-pyrazol-4-yl)-pyridin-2-yl-
amine] was synthesized by WuXi AppTec (Shanghai, China) 
and formulated in distilled water for in vivo study. Injectable 
cisplatin for clinical use (10 mg/vial) was purchased from Qilu 
Pharmaceutical Co., Ltd (Jinan, Shandong, China). Tumor tis-
sues were cut into small fragments of approximately 30 mm3 
under sterile conditions. BALB/c nude mice were implanted sub-
cutaneously with a tumor fragment by using a trocar. When the 
average tumor size reached 150 to 200 mm3, tumor size–matched 
mice were randomly assigned to four groups with six or seven 
mice in each group. The tumor-bearing mice were given ALK 
inhibitor crizotinib at 25 and 50 mg/kg (by mouth daily), cisplatin 
at 3 mg/kg (by intraperitoneal, every week), or vehicle alone for 
3 weeks. Tumor volumes and body weights were measured using 
calipers twice a week. The difference in tumor volumes between 
treatment groups was analyzed for significance using one-way 
analysis of variance followed by Dunnett’s test. The p value less 
than 0.05 was considered to be statistically significant.
RESULTS
In the past 2 years, we established more than 150 trans-
plantable lung cancer PDX models from Chinese lung cancer 
patients. The first 99 of the 150 models, consisting of 96 with 
NSCLC, were used in this study, and their clinical informa-
tion is summarized in Supplementary Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A526).
Detection of ALK Rearrangement in Lung 
Cancer PDX Models by Nanostring Fusion Assay
To identify ALK rearrangements, RNA samples isolated 
from xenograft tissues of 99 models were analyzed by a com-
bination of ALK 3′ overexpression- and ALK fusion-specific 
assays using NanoString’s nCounter technology. Because ALK 
is generally not expressed in normal adult tissues, ALK 3′ over-
expression in lung cancer was indicative of an ALK rearrange-
ment. In the ALK 3′ overexpression assay, we found that two 
NSCLC models, LU-01-0015 and LU-01-0319, exhibited ALK 
3′ overexpression as shown in Figure 1A with an ALK 3′ over-
expression score (ALK3 ′/5′ ratio) of 6.19 and 7.28, respectively 
(Fig. 1B). These results show that ALK is overexpressed in both 
NSCLC models, implicating ALK rearrangements.
ALK fusion partner–specific 5′ capture probes and ALK-
specific 3′ reporter probes were designed to detect the presence 
of preselected ALK fusion partners as previously described.22 
Most ALK fusion variants share the same 3′ portion of ALK 
starting with exon 20. Thus, a common reporter probe (desig-
nated as ALK exon 20), paired with capture probes targeting 
different ALK fusion partners and variants, was able to detect 
the preselected fusion transcripts containing ALK exon 20 
sequences, including all major variants of EML4–ALK fusions 
(variants 1, 2, 3a, 5, and V5) and KIF5B–ALK and TFG–ALK 
rearrangements. A reporter count of 60 was designated as the 
background threshold level, and the fusion was called present 
if the normalized reporter count was higher than background 
threshold. Among two models, LU-01-0319 showed higher 
reporter counts than the fusion reporter threshold, suggesting 
that it harbored the preselected fusion (Fig. 1C). Conversely, 
the reporter counts detected by the ALK exon 20 reporter 
were below the threshold in LU-01-0015. The data indicate 
that LU-01-0015 likely harbored a novel ALK fusion variant, 
which was not detectable by using the probe sets specific for 
known fusion genes indicated above.
Confirmation of ALK Overexpression in LU-
01-0015 and LU-01-0319 by Microarray
The gene expression profiles of 29 lung cancer PDX 
models, including LU-01-0015 and LU-01-0319, were ana-
lyzed by a GeneChip PrimeView Human Gene Expression 
Array (Affymetrix; 7 models) or GeneChip Human Genome 
U133 Plus 2.0 Array (Affymetrix; 22 models). Analyses of ALK 
expression revealed that ALK mRNA levels in both LU-01-
0015 and LU-01-0319 were markedly higher than in the other 
PDX models (Fig. 1D). These results provide further evidence 
for the presence of ALK rearrangements in both models.
Identification of HIP1–ALK by RNA-Seq
To identify ALK fusion variants in LU-01-0015 and 
LU-01-0319, we used massively parallel, paired-end sequenc-
ing of expressed transcripts (RNA-Seq) to detect gene fusions 
as described in Materials and Methods. The RNA-Seq produced 
approximately 80.9 million and 105.5 million paired reads (100 
base pair/read) for LU-01-0015 and LU-01-0319, respectively. 
Data analyses revealed that the ALK fusion gene in LU-01-
0319 was a known EML4–ALK variant 3a/b, which was cre-
ated by the breakage and intrachromosomal rearrangement of 
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chromosome 2 (Fig. 2A and B).28 Of special interest is the iden-
tification of huntingtin interacting protein 1 (HIP1) as a novel 
fusion partner of ALK in the second model LU-01-0015 (Fig. 
2A and B). HIP1–ALK rearrangement was formed by breakage 
and rejoining of chromosomes 7 and 2. Sixteen spanning reads 
and 2 spanning mate pairs were aligned to the cDNA break-
points of HIP1 and ALK genes, which revealed a fusion product 
formed by exon 28 of HIP1 fused to exon 20 of ALK (Fig. 2B).
Validation of ALK Fusions in Both 
Primary Tumors and Xenografts by 
RT-PCR and Direct Sequencing
To further confirm the fusion transcripts, RT-PCR was 
conducted by using forward- and reverse-primer combina-
tions pairing the sequences flanking the breakpoint detected 
by RNA-Seq. Subsequent sequencing of cDNA confirmed 
the presence of HIP1–ALK rearrangement in both the 
FIGURE 1.  Detection of ALK rearrangements and overexpression of the ALK gene in two NSCLC PDX models. A, Quantification 
of ALK 5′ and 3′ expression levels using the NanoString ALK fusion assay. B, ALK 3′ overexpression in both models as measured 
by ALK 3′/5′ score in the fusion assay. A background threshold of twofold was denoted by a horizontal dash line (B). C, ALK exon 
20 reporter counts detected in NanoString assay. A background threshold of 60 reporter counts was denoted by a horizontal 
dash line (B). D, Expression levels of ALK in NSCLC PDX models determined by a GeneChip PrimeView human gene expres-
sion array or a GeneChip Human Genome U133 Plus 2.0 array in a panel of 22 and seven models, respectively. ALK, anaplastic 
lymphoma kinase; PDX, patient–derived xenograft; NSCLC, non–small-cell lung cancer.
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primary tumor and xenograft of LU-01-0015 (Fig. 3A and 
B, left panels). In the predicted fusion protein, the majority 
of N-terminal of HIP1 encompassing the AP180 N-terminal 
homology (ANTH), the coiled-coil domain (CC) and a portion 
of the talin homology domain (TH) was fused upstream the 
intracellular juxtamembrane region of ALK (Fig. 3C). The 
cDNA corresponding to the mRNA of HIP1–ALK in both 
patient and xenograft tumors were cloned and its complete 
FIGURE 2.  Identification of a novel HIP1–ALK fusion by RNA-Seq. A, Circos plots depicting ALK rearrangements in LU-01-0015 
and LU-01-0319. Chromosomes were drawn to scale around the rim of the circle, and data are plotted on these coordinates. 
The blue arc and red arc represent intrachromosomal and interchromosomal translocation, respectively. B, Representative 
aligned reads were shown to map across the exon–exon fusion junction between HIP1 or EML4 and exon 20 of ALK in LU-01-
0015 and LU-01-0319, respectively, as illustrated in the schematic diagram. In LU-01-0319, the split-reads are shown align-
ing on the breakpoints of EML4–ALK variant 3a (A) and 3b (B). ALK, anaplastic lymphoma kinase; HIP1, huntingtin interacting 
protein 1; EML4, echinoderm microtubule-associated protein-like 4.
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nucleotide sequence was determined by direct sequencing. 
The data revealed one nonsynonymous single-nucleotide 
polymorphism (SNP) in HIP1 portion, one synonymous SNP, 
three nonsynonymous SNPs in coding sequence, and one 
insertion and one SNP in 3′-untranslated region of ALK por-
tion (Supplementary Figure 1A and 1B; Supplemental Digital 
Content 2, http://links.lww.com/JTO/A527). Compared with 
HIP1–ALK fusion of patient tumor, no secondary mutations 
were identified in the xenograft tumor. The cDNA contained 
an open reading frame coding for a protein of 1526 amino 
acids resulting from the in-frame fusion of the HIP1 N ter-
minus (residues 1–963) with the ALK C terminus (resi-
dues 1058–1620) (Supplementary Figure 1C; Supplemental 
Digital Content 2, http://links.lww.com/JTO/A527).
In LU-01-0319, EML4–ALK variants 3a and 3b were 
verified in both the primary tumor and xenograft (Fig. 3A and 
B, right panels). Analysis of sequence chromatograms sug-
gested that EML4–ALK variant 3b was the dominant isoform 
in the xenograft tumor, as the dominant peaks corresponded 
to variant 3b whereas the baseline noise peaks corresponded 
to variant 3a (Fig. 3B, lower right panel). Interestingly, expres-
sion level differences between variants 3a and 3b in the pri-
mary tumor were less remarkable in PDX tumors as the two 
peaks in a sequencing chromatogram of primary tumor over-
lapped with equal heights (Fig. 3B, upper right panel). These 
results suggest that EML4–ALK variant 3b was enriched dur-
ing the establishment and/or serial passaging of PDX tumors.
PDX Tumors Retained Histopathological 
Characterizations of the Primary Tumors 
from Which They Were Derived
ALK-rearranged NSCLC PDX models LU-01-0015 
and LU-01-0319 were serially xenografted up to passage 3 in 
BALB/c nude mice. PDX tumors maintained a similar growth 
pattern on serial xenotransplantation (Fig. 4). Histopathology 
of primary and xenograft tumors was further evaluated by a 
pathologist. Both LU-01-0015 and LU-01-0319 were diag-
nosed as moderately differentiated squamous cell carcinoma, 
FIGURE 3.  Validation of ALK rearrangements by RT-PCR and direct sequencing. A, RT-PCR products corresponding to HIP1–ALK 
and EML4–ALK fusion genes, respectively, in both the primary patient (PA) and PDX tissues. M, DNA ladder. B, Direct sequenc-
ing of cDNA revealed fusion junctions of HIP1–ALK and EML4–ALK translocations in LU-01-0015 and LU-01-0319, respectively. 
The corresponding locations of the genes were indicated by color-coded bars. C, Schematic representation of HIP1–ALK protein. 
Regions corresponding to HIP1 and ALK were shown in blue and red, respectively. The fusion protein joins the tyrosine kinase 
domain of ALK to the TH domain of HIP1. RT-PCR, reverse transcription polymerase chain reaction; ALK, anaplastic lymphoma 
kinase; HIP1, huntingtin interacting protein 1; EML4, echinoderm microtubule-associated protein-like 4; PA, primary patient; 
PDX, patient-derived xenograft; TH, talin homology.
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shown by the representative images of the primary tumors 
(Fig. 4, PA). Resection of the primary tumor from which 
LU-01-0015 was derived revealed a stage T3N1M0 NSCLC 
in a 62-year-old male patient with a 20-year smoking history. 
The primary tumor, which gave rise to LU-01-0319, was of 
stage T2N2M0 NSCLC in a 40-year-old male patient with-
out a smoking history. The presence of keratin was observed 
in both primary and xenograft tumors of LU-01-0319 but 
barely existed in LU-01-0015. Xenografts at various pas-
sages truthfully recapitulated the heterogeneity of the primary 
tumors and retained histopathological features as squamous 
cell carcinoma (Fig. 4, P0–P3). These results showed that 
PDX tumors retained the histological features of the original 
tumors, exhibiting a concordance between xenografts and the 
parental patient tumors.
To further confirm the histology of squamous cell car-
cinoma of both cases, immunohistochemistry was performed 
using a panel of differentiation markers, including CK5/6, 
34βE12, P63, BerEP4, and MOC31. CK5/6, p63, and 34βE12 
are the markers for squamous cell carcinoma. MOC31 and 
BerEP4 are expressed only in adenocarcinoma. The presence 
of CK5/6, p63, and 34βE12 expression and the absence of 
MOC31 and BerEP4 expression in both patient samples and 
PDX tissues confirm that both cases belong to squamous cell 
carcinoma (Supplementary Figure 2, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A528).
Responses of ALK-Rearranged NSCLC 
PDX Models to Crizotinib
To elucidate the functional significance of ALK trans-
locations, especially the novel HIP1–ALK fusion, in estab-
lished PDX models, we then tested the responses of both 
models to crizotinib. An ALK wild-type model LU-01-0030 
was randomly selected as a control (Supplementary Table 1, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A526). When the average tumor sizes reached 150 to 200 mm3, 
tumor-bearing animals were given crizotinib at 25 or 50 mg/kg 
(by mouth daily) or cisplatin at 3 mg/kg (by intraperitoneal, 
every week) or vehicle alone for 3 weeks. The results show 
that the average tumor volumes in crizotinib-treated groups 
were significantly less than those in the control groups in 
both LU-01-0015 and LU-01-0319, demonstrating that both 
models were sensitive to ALK inhibition (Fig. 5). Conversely, 
ALK wild-type model LU-01-0030 was resistant to crizotinib 
treatment. Differential responses to the standard-of-care drug, 
cisplatin, were observed in three models (Fig. 5).
FIGURE 4.  The histology of ALK-rearranged NSCLC patient (PA) and serially passaged PDX tumors and the growth curves of 
corresponding PDX tumors. The growth characteristics were summarized in the tables on the left. T250 and T500: the number 
of days required for a tumor to reach 250 mm3 and 500 mm3, respectively. T500-T250: the number of days required for a tumor 
to grow from 250 mm3 to 500 mm3. PDX, patient-derived xenograft; ALK, anaplastic lymphoma kinase; HIP1, huntingtin inter-
acting protein 1; EML4, echinoderm microtubule-associated protein-like 4; NSCLC, non–small-cell lung cancer.
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DISCUSSION
In the present study, we first screened ALK rearrange-
ments in 99 established lung cancer PDX models by the 
NanoString ALK fusion assay (NanoString Technologies, Inc.). 
ALK rearrangements were identified in two NSCLC models 
(2%), which both also exhibited elevated ALK mRNA. Total 
RNA isolated from both xenograft tumors were subjected to 
RNA-Seq analyses. In addition to a previously known EML4–
ALK fusion in one model, HIP1 was identified as a novel part-
ner of ALK rearrangement in the other. RT-PCR and direct 
sequencing analyses of both primary tumor and xenograft 
elucidated that exon 28 of the HIP1 gene fused to a common 
breakpoint on exon 20 of the ALK gene. Furthermore, tak-
ing the advantage of available PDX models, we evaluated the 
effect of crizotinib in ALK wild-type, HIP1–ALK- and EML4–
ALK-rearranged NSCLC PDX models, respectively. The 
results showed that, similar to the EML4–ALK-positive tumor, 
the HIP1–ALK-rearranged tumor responded sensitively to the 
treatment of crizotinib, whereas an ALK wild-type tumor did 
not respond to the treatment. Overall, our study not only iden-
tified HIP1 as a novel fusion partner of ALK in NSCLC, but 
also demonstrated the sensitivity of the HIP1–ALK rearrange-
ment to crizotinib, warranting future clinical applications of 
crizotinib in HIP1–ALK-positive NSCLCs.
A subset of NSCLC harbors an inversion within chromo-
some 2 that gives rise to a transforming fusion gene, EML4–
ALK, which encodes an activated protein tyrosine kinase. An 
EML4–ALK rearrangement in a lung adenocarcinoma was 
first identified in 2007.28 Such a fusion gene was also revealed 
in a lung adenocarcinoma cell line H2228.29 The discovery of 
the EML4–ALK fusion gene successfully promoted clinical 
trials in a subset of NSCLC harboring EML4–ALK fusion and 
led to the rapid approval of ALK inhibitor crizotinib by U.S. 
Food and Drug Administration.
Multiple isoforms of EML4–ALK gene fusion have been 
discovered. In NSCLC, in addition to EML4, other genes are 
frequently fused to the ALK gene because of the presence of 
a common fragile locus within intron 19 of the ALK gene. 
Noteworthy examples include KIF5B–ALK, KLC1–ALK, and 
TFG–ALK in NSCLC.21
HIP1 belongs to the huntingtin interacting protein fam-
ily (HIP1 and HIP1R in mammals and Sla2p in yeast), which 
plays a role in clathrin-mediated endocytosis and receptor 
trafficking.30–32 It consists of an N-terminally localized AP180 
N-terminal homology domain (ANTH), a central coiled-coil 
domain (CC), and a talin homology domain (TH) at the C termi-
nus (Fig. 3D).32,33 Fusion of HIP1 with PDGFβR was previously 
reported in a patient with chronic myelomonocytic leukemia 
FIGURE 5.  Antitumor activity of crizotinib in ALK wild-type, and HIP1–ALK- and EML4–ALK-rearranged NSCLC PDX models. 
Crizotinib (by mouth, daily) or cisplatin (by intraperitoneal every week) were administered in tumor-bearing mice for 3 weeks 
(n=6 or 7 in each group). Data were shown as mean ± standard error of the mean. In both ALK-rearranged models the average 
tumor volumes in the crizotinib- or cisplatin-treated groups at the endpoint are significantly less than the vehicle control group 
as determined using one-way analysis of variance. *p < 0.005, **p< 0.01, **p< 0.001. ALK, anaplastic lymphoma kinase; EML4, 
echinoderm microtubule-associated protein-like 4; HIP1, huntingtin interacting protein 1; PDX, patient-derived xenograft; 
NSCLC, non–small-cell lung cancer; WT, wild type.
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with t(5;7)(q33; q11.2) translocation, in which the HIP1 gene 
located at 7q11.2 (i.e., exon 30) fused with the PDGFβR gene 
on 5q33.34 When expressed in the murine hematopoietic cell 
line, Ba/F3, HIP1–PDGFβR fusion protein becomes constitu-
tively tyrosine phosphorylated and transforms the Ba/F3 cells 
to interleukin-3–independent growth, implicating its role in 
pathogenesis of hematopoietic malignancies.34,35 A subsequent 
study demonstrated that transgenic overexpression of HIP1 is 
associated with the development of lymphoid neoplasms and, 
therefore, HIP1 plays an important role in the transformation 
of lymphoid cells.32 In the present study, instead of exon 30, 
exon 28 of the HIP1 gene fused with exon 20 of the ALK gene 
in an NSCLC patient. These findings indicate that different iso-
forms of HIP1–ALK may exist. Analysis of novel HIP1–ALK 
translocations should contribute to our understanding of the 
pathogenesis of a subset of NSCLC. Although the molecular 
mechanism of transformation of HIP1–ALK translocations in 
lung carcinogenesis is still under investigation, the elevated 
ALK mRNA and in vivo efficacy caused by ALK inhibition 
suggest that fusion of HIP1 with ALK in NSCLC results in 
constitutive activation of ALK and triggers oncogenic cascade, 
as does the EML4–ALK fusion gene.
HIP1–ALK cDNAs were obtained from total RNA isolated 
from both patient and PDX (P3) tissues, and then analyzed to elu-
cidate the full coding sequence of the fusion gene. Interestingly, 
both sequences obtained from the patient sample and PDX tissue 
are identical, suggesting that no secondary mutation occurs after 
xenotransplantation (Supplementary Figure 1A–C; Supplemental 
Digital Content 2, http://links.lww.com/JTO/A527).
In light of the facts that ALK rearragement predominantly 
exist in lung adenocarcinoma,36–39 it is interesting to note that, 
in our study, both cases of ALK rearrangements were squamous 
cell carcinoma. Apparently, the presence of EML4–ALK rear-
rangements has been described in various histological types 
of NSCLC, including squamous cell carcinoma,3,5,29 adeno-
squamous cancer,36 and adenocarcinoma with additional squa-
mous or sarcomatoid differentiation.40 Therefore, although the 
frequency of ALK translocations seems to be lower than lung 
adenocarcinoma, other histological types of lung cancer also 
harbor ALK rearrangements. Preferable propagation of squa-
mous cell carcinoma on xenotransplantation most likely con-
tributes to the discovery of ALK rearrangements in two cases of 
squamous cell carcinoma reported in this study. In fact, the sim-
ilar numbers of squamous cell carcinoma and adenocarcinoma 
patient samples were implanted; however, among the 99 lung 
cancer PDX models generated, adenocarcinoma and squamous 
cell carcinoma comprised 15% and 69%, respectively. These 
results suggest that the success rate of squmaous cell carcinoma 
is approximately fourfold higher than that of adenocarcinoma 
at xenotransplation. Higher frequency of squamous cell carci-
noma increases its chance of detection of ALK rearrangement in 
the selected population of PDX models.
Among ALK fusion variants identified in NSCLC, 
including EML4–ALK, KIF5B–ALK, KLC1–ALK, TFG–ALK, 
and ALK–PTPN3, the transforming potentials of the EML4–
ALK, KIF5B–ALK, and KLC1–ALK fusion genes have been 
shown previously, implicating their role as oncogenic drivers 
of lung carcinogenesis.3,18,19,28,41 The biological significance 
of other ALK fusion variants requires future investigation. 
However, inhibition of the catalytic activity of the ALK gene 
is required for ALK inhibition. It has been predicted that ALK–
PTPN3 does not respond to crizotinib treatment because of its 
lack of the kinase domain.
In the present study, the response of the HIP1–ALK-
positive tumor to the treatment of crizotinib in the PDX model 
provides evidence of its oncogenic activity. Therefore, unlike 
several other ALK rearrangements in NSCLC, our studies 
provide evidence of the biological and clinical significance 
of HIP1–ALK fusion. As is the case for EML4–ALK translo-
cations, HIP1–ALK may serve as a predictive biomarker for 
crizotinib treatment because HIP1–ALK confers sensitivity to 
the ALK inhibitor crizotinib. Patients with this chromosomal 
translocation most likely would derive clinical benefit from 
specific ALK inhibition. The frequency of HIP1–ALK fusion 
is 1% in our cohort (n=99). The incidence of the fusion should 
be investigated in a larger cohort of NSCLC.
Clearly, PDX models preserve the genetic and histo-
logical heterogeneity of clinical patient tumors. Three of the 
NSCLC models studied here showed differential responses 
to the chemotherapy drug cisplatin, representing heterogenic 
responses to standard-of-care therapy observed in the patient 
population in the clinic. These xenografts have recently 
emerged as an excellent preclinical model for drug testing. 
Established PDX models harboring either EML4–ALK or 
HIP1–ALK fusion genes offer a test system for evaluating the 
next generation of ALK inhibitors under active development. 
Furthermore, to support discovery efforts and to better under-
stand the mechanisms for drug resistance, we have initiated 
the development of crizotinib-resistant models in both EML4–
ALK- and HIP1–ALK-containing PDX models in mice.
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